We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




PEPFAR and BD Improve African Blood Collection Safety

By LabMedica International staff writers
Posted on 18 Aug 2009
United States officials have signed a partnership agreement with Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA), launching an initiative to improve blood collection safety in clinics and hospitals in sub-Saharan Africa. More...
The aim of the pact is to protect healthcare personnel and patients in African countries from infectious agents such as human immunodeficiency virus (HIV) that are transmitted by blood.

A Memorandum of Understanding was signed in Washington on August 11, 2009 by Ambassador Elizabeth Bagley, the U.S. Department of State special representative for global partnerships (Washington DC, USA), and Gary M. Cohen, executive vice president of BD.

Safer blood collection has become critical in sub-Saharan nations and other emerging African countries, which are severely impacted by the HIV/AIDS pandemic. Access to HIV treatment in these countries significantly increased in recent years and consequently has expanded the quantity of blood drawing for HIV screening and monitoring tests.

The three-year initiative--which may be extended up to two additional years--is scheduled to begin in Kenya and expand to include up to four additional U.S. President's Emergency Plan for AIDS Relief (PEPFAR)-supported countries. It will ultimately support in-service training for as many as 10,000 healthcare workers. When fully implemented, the monitoring component of the initiative aims to track as many as two million blood-draws within each participating country.

''The program will help hospital and clinical personnel improve their blood-drawing procedures and specimen handling, processes that are critical to the proper management of HIV/AIDS patients,'' said the State Department (Washington DC, USA) release. In addition, "… [it] will help prevent needle stick injuries by establishing or enhancing needle stick-injury surveillance. These monitoring measures can identify practices that pose risks to health workers and patients.''

Ministries of Health in participating countries will develop individualized policies, guidelines, and standard operating procedures for blood drawing and specimen handling.

Related Links:
U.S. Global Partnership Initiative, the Department of State
Becton, Dickinson and Company
PEPFAR


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.